Back to search

Article

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters

2022-10-25

Abstract excerpt

<h4>ABSTRACT</h4> Waning immunity following mRNA vaccination and the emergence of SARS-CoV-2 variants has led to reduced mRNA vaccine efficacy against both symptomatic infection and severe disease. Bivalent mRNA boosters expressing the Omicron BA.5 and ancestral WA1/2020 Spike proteins have been developed and approved, because BA.5 is currently the dominant SARS-CoV-2 variant and substantially evades neutralizing...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c3927f71-bf94-5e4a-8ee4-68d9fdb7245e
DOI
10.1101/2022.10.24.513619
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunogenicity of the BA.5 Bivalent mRNA Vaccine BoostersDOI 10.1101/2022.10.24.513619
Immunogenicity of BA.5 Bivalent mRNA Vaccine BoostersSemantic proximity
Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shotSemantic proximity
Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Semantic proximity
Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccineSemantic proximity
Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5Semantic proximity
Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variantsSemantic proximity
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical TrialSemantic proximity
Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron subvariants BA.2, BA.2.12.1 and BA.5Semantic proximity
Safety and Immunogenicity of XBB.1.5-Containing mRNA VaccinesSemantic proximity
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim resultsSemantic proximity
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5Semantic proximity
Select a neighboring publication to make it the new centre.